


Immunothérapie et cancer digestifs

Dr David Sefrioui, Quoi de Neuf en Hépatogastroenterologie 2016


Carcinogénèse et ciblage thérapeutique




Carcinogénèse et ciblage thérapeutique



Carcinogénèse et ciblage thérapeutique




Types d'immunothérapie




Mécanismes d'action

Checkpoint 1 : CTLA4



Checkpoint 2 : PD1/PDL1




Postow et al. Journal of Clinical Oncology 2015

Ipililumab (Yervoy[®], BMS),


Nivolumab (OPDIVO[®], BMS)

Pembrolizumab (KEYTRUDA[®], MSD)

Données d'efficacité



Données d'efficacité



PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, and L.A. Diaz, Jr.

New England Journal of Medicine, juin 2015

Etude de phase 2

41 patients

Pembrolizumab 10 mg/kg tous les


14 jours

CCR MSI = 11

CCR non MSI = 21

Cancer MSI non CR = 9

29/41 (71%) ≥ 3^e ligne CT



Le et al. New England Journal of Medicine 2015

Type of Response	Mismatch Repair-Deficient Colorectal Cancer (N=10)	Mismatch Repair-Proficient Colorectal Cancer (N=18)	Mismatch Repair-Deficient Noncolorectal Cancer (N=7)
Complete response — no. (%)	0	0	1 (14)*
Partial response — no. (%)	4 (40)	0	4 (57)†
Stable disease at week 12 — no. (%)	5 (50)	2 (11)	0
Progressive disease — no. (%)	1 (10)	11 (61)	2 (29)
Could not be evaluated — no. (%)‡	0	5 (28)	0
Objective response rate (95% CI) — %	40 (12–74)	0 (0–19)	71 (29–96)
Disease control rate (95% CI) — %§	90 (55–100)	11 (1–35)	71 (29–96)

Le et al. New England Journal of Medicine 2015

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, and L.A. Diaz, Jr.

New England Journal of Medicine, juin 2015

Etude de phase 2

41 patients

Pembrolizumab 10 mg/kg tous les


14 jours

CCR MSI = 11

CCR non MSI = 21

Cancer MSI non CR = 9

29/41 (71%) ≥ 3^e ligne CT



Le et al. New England Journal of Medicine 2015

Type of Response	Mismatch Repair-Deficient Colorectal Cancer (N=10)	Mismatch Repair-Proficient Colorectal Cancer (N=18)	Mismatch Repair-Deficient Noncolorectal Cancer (N=7)
Complete response — no. (%)	0	0	1 (14)*
Partial response — no. (%)	4 (40)	0	4 (57)†
Stable disease at week 12 — no. (%)	5 (50)	2 (11)	0
Progressive disease — no. (%)	1 (10)	11 (61)	2 (29)
Could not be evaluated — no. (%)‡	0	5 (28)	0
Objective response rate (95% CI) — %	40 (12–74)	0 (0–19)	71 (29–96)
Disease control rate (95% CI) — %§	90 (55–100)	11 (1–35)	71 (29–96)

Le et al. New England Journal of Medicine 2015

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, and L.A. Diaz, Jr.

New England Journal of Medicine, juin 2015

Etude de phase 2

41 patients

Pembrolizumab 10 mg/kg tous les

14 jours

CCR MSI = 11



CCR non MSI = 21

Cancer MSI non CR = 9

29/41 (71%) \geq 3^e ligne CT

SSP = 2.2 mois (MSS) versus NA (MSI)

SG = 5.5 mois (MSS) versus NA (MSI)



Autres données d'efficacité

Etude	Type tumoral	Ligne CT	TTT	EI (gr 3-4)	résultats
Phase II ^a	CCRm (n=82)	≥3 ^e L	Nivo (3mg/kg) Nivo + Ipil	10% 26%	SSP = 5.3m;SG=17.1 m SSP =NA; SG = NA
Phase II ^b	Canal anal M+ (n=37)	≥2 ^e L	Nivo (3mg/kg)	15%	RO =24%; SSP = 3.9m
Phase I ^c	CHC avancé (n=51)	≥2 ^e L	Nivo (3mg/kg)	20%	TC=65% (RO=15% S=50%);SG=14.1 m
Phase I-II ^d	Gastrique avancé (n=160)	≥3 ^e L	N3 (4C) p. N3 N1+ I3 (4C) p. N3 N3 + I1 (4C) p. N3	17% 45% 27%	SG=5m SG = 6.9m SG=4.8m


^a Overman et al. OS 3501 ASCO 2016

^b Morris et al. OS 3503 ASCO 2016

^c El Khouery et al. PDS 4012 ASCO 2016


^d Janjigian et al. PDS 4010 ASCO 2016

Toxicité



Michot et al. European Journal of Cancer 2016


Toxicité



Rash cutané, prurit :

- Fréquent : 40% (monothérapie) et 60 % (combinaison)
- Précoce : 2 à 4 semaines
- \geq Grade 3 < 10%
- Autres = Syndrome Stevens-Johnson, Lyell ou vitiligo

Toxicité



Rash cutané, prurit :

- Fréquent : 40% (monothérapie) et 60 % (combinaison)
- Précoce : 2 à 4 semaines
- \geq Grade 3 < 10%
- Autres = Syndrome Stevens-Johnson, Lyell ou vitiligo

Diarrhée:

- Fréquent : 15-20% (P et N) et 20-30% (I) et 40 % (combinaison)
- \geq Grade 3 = 2% (P, N); 6% (I) et 9% (combinaison)
- retardé: médiane = 6 à 8 semaines après le début du ttt

Hépatite (<5%); pneumopathie (2%), dysthyroidie (5-10%), asthénie (20à 30% (gr. 1-2)

Conclusion

1. Nouvelle arme dans l'arsenal thérapeutique
 - Inhibiteur check point immunitaire : PD1 et CTLA4
2. Signaux d'efficacité (CCRm MSI, CHC avancé, Oesogastrique avancé, Canal anal M+)
3. Ouverture prochaine du Protocole CA209-577 (BMS)

étude de phase III multicentrique, randomisée, en double aveugle, évaluant le nivolumab versus placebo en tant que traitement adjuvant chez des sujets ayant eu une résection complète d'un cancer de l'œsophage (CO) ou de la jonction œsogastrique (JOG) et ayant reçu une radio-chimiothérapie (CRT) préalablement à la résection chirurgicale, c'est à dire neo-adjuvante

Toxicité

AEOSI (Grade)

(acc. NCI CTC v.4)

Examinations

For the detailed laboratory panel please refer to Table 4

Management

Anti-PD-1 therapy / Methylprednisolone or equivalent^a

Follow-up

↗ Improvement
→ No change
↘ Worsening

Skin events					
°1		●	Topical steroid ^b		
°2		●	Topical steroid ^b		
°3-4	(⊕Skin biopsy)	▲ or ■	1.0-2.0 mg/kg/d	↗ : ●	
Diarrhea/Colitis					
°1	Stool test on pathogens	●	---		
°2	(⊕ Colonoscopy)	▲	0.5-1.0 mg/kg/d	→ : ■	
°3-4	Colonoscopy	■	1.0-2.0 mg/kg/d	→ / ↘ : Infiximab <i>Cave!</i> ^d	
Pneumonitis					
°1	Frequent controls [q2-3d]	●	---		
°2	Daily symptom contr.; (⊕ Bronchoscopy)	▲	1.0-2.0 mg/kg/d	↗ : ●	
°3-4	Bronchoscopy/biopsy	■	2.0-4.0 mg/kg/d	→ / ↘ : Immunosuppr. therapy ^e	
Endocrine events		<i>Please refer primarily to full-text section for adequate guidance with regard to complex features of AEOSI</i>			
Asymptomatic °1	Regular controls; (⊕ Imaging)	●	---		
Symptomatic °2	} Regular controls; (⊕ Imaging; ⊕ Further diagnostics)	▲	(⊕HRT); 1.0-2.0 mg/kg/d	↗ : ●	→ : Start/maintain HRT
		▲	(⊕ HRT); i.v. steroids ^g	↗ : ●	Regular controls
°3-4					
Renal events					
°1	Control for signs of renal dysfunction	●	---		
°2	(⊕Renal biopsy); Creatinine [q2-3d]	▲	0.5-1.0 mg/kg/d	↗ : ●	
°3-4	(⊕Renal biopsy)	■	1.0-2.0 mg/kg/d		
Hepatic events					
°1	Control for signs of hepatitis	●	---		
°2	Frequent controls [transaminases]	▲	0.5-1.0 mg/kg/d	↗ : ●	
°3-4	Very frequent contr. [q1-2d]; (⊕Biopsy)	■	1.0-2.0 mg/kg/d	→ / ↘ : Immunosuppr. therapy ^e	
Infusion reactions ^h					
°3-4	Vigilant controls/monitoring	■	2.0-4.0 mg/kg/d or i.v. corticosteroids ≥ antihistamines		

Legend: ● continue therapy (Anti-PD-1); ▲ delay therapy (Anti-PD-1); ■ stop therapy (Anti-PD-1);
(⊕): optional, i.e. I consider it